5/22/2024  4:48:51 PM Chg. +6.34 Volume Bid4:49:11 PM Ask4:49:11 PM Market Capitalization Dividend Y. P/E Ratio
98.42USD +6.88% 25,568
Turnover: 2.47 mill.
98.36Bid Size: 200 98.66Ask Size: 100 -USD - -

Business description

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
 

Management board & Supervisory board

CEO
Ugur Sahin
Management board
Jens Holstein, Özlem Türeci, Ryan Richardson, Sean Marett, Sierk Poetting
Supervisory board
Helmut Jeggle, Michael Motschmann, Prof. Christoph Huber, Ulrich Wandschneider
 

Company data

Name: BioNTech SE
Address: An der Goldgrube 12,DE-55131 Mainz
Phone: +49-6131-9084-0
Fax: +49-6131-9084-390
E-mail: info@biontech.de
Internet: https://biontech.de/de
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: -
IPO date: -

Investor relations

Name: Dr. Sylke Maas
IR phone: -
IR Fax: -
IR e-mail: Investors@biontech.de

Company calendar

CW 32 | 8/5/2024 Interim Report 2nd Quarter/6 Months
CW 45 | 11/4/2024 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

AT Impf GmbH
 
50.33%
Freefloat
 
19.70%
Medine GmbH
 
18.38%
MIG Verwaltungs AG
 
5.98%
FMR LLC
 
5.61%